Condition: Metastatic Breast Cancer · Hyperinsulinism · Hyperglycemia Drug Induced · Sponsor: Rambam Health Care Campus
The goal of this study is to test whether monitoring insulin levels and using pioglitazone to treat hyperglycemia and hyperinsulinemia in patients treated with Alpelisib for metastatic breast cancer is feasible and safe, and to assess the rates of glycemic control, dose reductions and treatment discontinuation and the progression free survival of patients treated with this regimen.
This description comes directly from the study's public registry record.
Ayelet Shai, MD · +972-4-777-6700 · a_shai@rambam.health.gov.il
Always discuss trial participation with your own doctor first.
| Rambam Health Care Campus | Haifa, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05753657